Posted by Michael Wonder on 21 Jul 2026
Almirall announces EMA acceptance for filing of paediatric registration of Ebglyss (lebrikizumab) in atopic dermatitis in children 6 months and older
20 July 2026 - The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase 3 ADorable-1 study and the ADorable-2 long-term extension study.
Almirall today announced that the EMA has accepted the submission of the extension of the Marketing Authorisation Application of Ebglyss (lebrikizumab) for the treatment of children and adolescents aged 6 months to <18 years and weighing below 40 kg with moderate to severe atopic dermatitis.
